BK2513 Drug Manufacturers - Specialty & Generic
- 885.452
- +5.936+0.67%
Piper Sandler Maintains Underweight On Canopy Growth Stock, Calls Cannabis Rescheduling 'Largely Symbolic'
A recent company note from Piper Sandler & Co, by senior analysts Michael S. Lavery and Luke Maloney offers insights into Canopy Growth Corporation's (NASDAQ:CGC) financial performance, valuation and
12 Health Care Stocks Moving In Friday's After-Market Session
GainersLiquidia (NASDAQ:LQDA) stock rose 12.7% to $14.5 during Friday's after-market session. The market value of their outstanding shares is at $1.1 billion. Adagene (NASDAQ:ADAG) shares moved upward
Cannabis Stock Gainers And Losers From May 31, 2024
GAINERS:Blueberries Medical (OTC:BBRRF) shares closed up 44.66% at $0.01Target Group (OTC:CBDY) shares closed up 21.43% at $0.00Cara Therapeutics (NASDAQ:CARA) shares closed up 8.61% at $0.65CV Scienc
Takeda Gets Positive Opinion From EU Regulators for CTTP Therapy
Takeda Gets Positive CHMP Opinion For Recombinant ADAMTS13 In Congenital Thrombotic Thrombocytopenic Purpura
cTTP Is an Ultra-rare, Potentially Fatal Blood-Clotting Disorder with Limited Treatment Options; Untreated, Acute TTP Events Have a Mortality Rate of >90%1,2If Approved in the European Union, rADAMTS1
Acreage's Q1 Revenue Slips 19% YoY But CEO Foresees 'Significant Growth Opportunities' As Canopy Growth Strategy Moves Forward
Multi-state cannabis operator Acreage Holdings, Inc. (CSE:ACRG, ACRG.B.U))) (OTCQX:ACRHF, ACRDF))), reported its financial results on Friday for the first quarter ended March 31, 2024."In the first qu
12 Health Care Stocks Moving In Friday's Pre-Market Session
GainersNovo Integrated Sciences (NASDAQ:NVOS) stock moved upwards by 69.6% to $0.77 during Friday's pre-market session. The company's market cap stands at $14.5 million. Adaptimmune Therapeutics (NASD
HC Wainwright & Co. Reiterates Buy on Cyclo Therapeutics, Maintains $3 Price Target
HC Wainwright & Co. analyst Swayampakula Ramakanth reiterates Cyclo Therapeutics (NASDAQ:CYTH) with a Buy and maintains $3 price target.
Cyclo Therapeutics Analyst Ratings
Date Upside/Downside Analyst Firm Price Target Change Rating Change Previous / Current Rating 05/31/2024 130.77% HC Wainwright & Co. $3 → $3 Reiterates Buy → Buy 05/01/2024 130.77% HC Wainwright & Co.
Earnings Call Summary | Canopy Growth(CGC.US) Q4 2024 Earnings Conference
The following is a summary of the Canopy Growth Corporation (CGC) Q4 2024 Earnings Call Transcript:Financial Performance:Reported Q4 FY24 organic revenue growth of 16% compared to Q4 FY23.Consolidated
Nektar, Verastem Among Healthcare Additions in Russell Microcap; Assertio, Sangamo Removed
12 Health Care Stocks Moving In Thursday's After-Market Session
GainersMyMD Pharmaceuticals (NASDAQ:MYMD) stock rose 46.0% to $2.89 during Thursday's after-market session. The market value of their outstanding shares is at $6.6 million. Adaptimmune Therapeutics (N
Russell 3000: Inovio, Ocugen Among Healthcare Additions; Assertio, Ginkgo Bioworks Among Deletions
Why American Eagle Outfitters Shares Are Trading Lower? Here Are Other Stocks Moving In Thursday's Mid-Day Session
Shares of American Eagle Outfitters, Inc. (NYSE:AEO) fell during Thursday's session following first-quarter results.American Eagle Outfitters reported adjusted earnings of 17 cents per share and quart
Here's How Much $100 Invested In Zoetis 10 Years Ago Would Be Worth Today
Zoetis (NYSE:ZTS) has outperformed the market over the past 10 years by 7.9% on an annualized basis producing an average annual return of 18.41%. Currently, Zoetis has a market capitalization of $79.2
12 Health Care Stocks Moving In Thursday's Intraday Session
GainersCue Health (NASDAQ:HLTH) shares rose 70.1% to $0.09 during Thursday's regular session. The market value of their outstanding shares is at $14.8 million. OneMedNet (NASDAQ:ONMD) shares increased
What's Going On With Canopy Growth Stock After Earnings?
Canopy Growth Corporation (NASDAQ:CGC) shares are trading higher Thursday after the company reported its fourth-quarter financial results before the market open. Here's a look at what to know. What To
4 Analysts Assess Teva Pharmaceutical Indus: What You Need To Know
In the latest quarter, 4 analysts provided ratings for Teva Pharmaceutical Indus (NYSE:TEVA), showcasing a mix of bullish and bearish perspectives.The following table encapsulates their recent ratings
Teva Pharmaceutical Indus Analyst Ratings
Date Upside/Downside Analyst Firm Price Target Change Rating Change Previous / Current Rating 05/30/2024 25.9% B of A Securities $18 → $21 Maintains Buy 05/13/2024 19.9% Piper Sandler $19 → $20 Reiter
Predictive Oncology, Augmedix, Cue Health Among Healthcare Movers